Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Canada
  4. CANADIAN NATIONAL STOCK EXCHANGE
  5. Mindset Pharma Inc.
  6. News
  7. Summary
    MSET   CA60268M1023

MINDSET PHARMA INC.

(MSET)
SummaryQuotesChartsNewsCompanyFinancials 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

Mindset Pharma Announces its Next Generation Novel 5-MeO-DMT Psychedelic Analogs Demonstrate a Significantly Improved Safety Profile in Preclinical Results

08/31/2021 | 07:31am EDT

TORONTO, Aug. 31, 2021 (GLOBE NEWSWIRE) -- Mindset Pharma Inc. (CSE: MSET) (FSE: 9DF) (OTCQB: MSSTF) ("Mindset" or the "Company"), a drug discovery and development company focused on creating optimized and patentable next-generation psychedelic medicines to treat neurological and psychiatric disorders with unmet medical needs, today announced that compounds from its Family 4, comprised of DMT/5-MeO-DMT inspired analogs, have demonstrated a significant decrease in serotonergic toxicity, which can cause a range of mild to life-threatening symptoms, in head-to-head preclinical comparisons. Furthermore, the results reaffirm the Company’s previous findings that its Family 4 drug candidates demonstrated superior efficacy compared to 5-MeO-DMT.

“DMT and 5-MeO-DMT both show promise as medicinal psychedelics due to their short duration of action and high potency. However, our studies suggest that serotonergic toxicity could represent a considerable health risk as patients are more broadly treated with psychedelics, potentially leading to high blood pressure, tremors, delirium and a range of other symptoms,” said James Lanthier, CEO of Mindset. “Our exciting preclinical results suggest that our next generation drug candidates have the potential to offer a safer and more convenient solution for clinic-based therapy.”

“In-vivo models confirmed potential safety concerns associated with serotonergic toxicity of 5-MeO-DMT, indicated by a higher number of instances of 5-HT syndrome compared to some of Mindset’s NCE compounds,” stated Joseph Araujo, Chief Scientific Officer of Mindset. “These results indicate the potential for 5-MeO-DMT to induce serotonin syndrome, which is a consequence of excess serotonin (5-HT) agonism and can lead to serious health complications. However, some of Mindset’s drug candidates showed no signs of inducing 5-HT syndrome, suggesting a significantly improved safety profile compared to 5-MeO-DMT. Mindset’s Family 4 compounds can potentially be developed with marked improvements in safety, efficacy, and duration of action compared to 5-MeO-DMT, making them more suitable for a wider range of indications.”

Mindset’s Family 4 compounds are DMT and 5-MeO-DMT inspired drug candidates that offer a broad range of pharmacological diversity suitable for in-clinic settings. The Company has run a battery of specialized in-vitro and in-vivo tests on its patent-pending novel compounds to select the optimal psychedelic drug candidates for progressing towards human clinical trials.

To watch a video of Mindset’s CEO discuss the announcement in greater detail, please visit: https://youtu.be/m3wcvwLHmUk.

For more information, please contact:

Investor Contact:
Allison Soss/Tim Regan
KCSA Strategic Communications
Email: MindSet@kcsa.com
Phone: 212-896-1267/ 347-487-6788

Company Contact:
James Lanthier, CEO
Email: jlanthier@mindsetpharma.com

Jason Atkinson, VP, Corporate Development
Email: jatkinson@mindsetpharma.com
Phone: 416-479-4094

About Mindset Pharma Inc.
Mindset Pharma Inc. is a drug discovery and development company focused on creating optimized and patentable next-generation psychedelic medicines to treat neurological and psychiatric disorders with unmet needs. Mindset was established in order to develop next generation pharmaceutical assets that leverage the breakthrough therapeutic potential of psychedelic drugs. Mindset is developing several novel families of next generation psychedelic compounds, as well as an innovative process to chemically synthesize psilocybin as well as its own proprietary compounds.

For further information on Mindset, please visit our website at www.mindsetpharma.com.

Forward-Looking Information

This news release contains certain "forward-looking information" within the meaning of applicable securities law. Forward looking information is frequently characterized by words such as "plan", "expect", "project", "intend", "believe", "anticipate", "estimate", "may", "will", "would", "potential", "proposed" and other similar words, or statements that certain events or conditions "may" or "will" occur. These statements are only predictions. Forward-looking information is based on the opinions and estimates of management at the date the information is provided and is subject to a variety of risks and uncertainties and other factors that could cause actual events or results to differ materially from those projected in the forward-looking information. Additional information regarding risks and uncertainties relating to the Company's business are contained under the heading "Risk Factors" in the Company's annual information form for the financial year ended June 30, 2020 dated March 5, 2021. The forward-looking information included in this news release is made as of the date of this news release and the Company does not undertake an obligation to publicly update such forward-looking information to reflect new information, subsequent events or otherwise, except as required by applicable law.

NEITHER THE CANADIAN SECURITIES EXCHANGE NOR ITS REGULATIONS SERVICES PROVIDER HAVE REVIEWED OR ACCEPTED RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.


Primary Logo


ę GlobeNewswire 2021
All news about MINDSET PHARMA INC.
10/18KCSA Psychedelics Virtual Investor Conference Presentations Available for On-Demand Vie..
AQ
10/14MINDSET PHARMA : Expands Benchmarking Data for First Generation Psychedelics Through the C..
AQ
10/14Mindset Pharma Expands Benchmarking Data for First Generation Psychedelics Through the ..
CI
10/11KCSA Psychedelics Virtual Investor Conference Agenda Announced for October 13th & 14th
AQ
09/29MINDSET PHARMA EXPANDS PIPELINE : Identifies Additional Next Generation 5-MeO-DMT-Inspired..
GL
09/29Mindset Pharma Expands Pipeline Identifies Additional Next Generation 5-MeO-DMT-Inspire..
CI
09/23Mindset Pharma Announces Inclusion in NYSE Listed AdvisorShares Psychedelics Exchange T..
GL
09/20Mindset Pharma Announces Further Preclinical Results Demonstrating Strong Efficacy and ..
GL
09/20Mindset Pharma Inc. Announces Further Preclinical Results Demonstrating Strong Efficacy..
CI
09/14MINDSET PHARMA : Further Validates Lead Candidate as Next Generation Psilocybin Analog Thr..
MT
More news
Financials
Sales 2020 - - -
Net income 2020 -0,64 M -0,52 M -0,52 M
Net cash 2020 0,54 M 0,44 M 0,44 M
P/E ratio 2020 -
Yield 2020 -
Capitalization 62,4 M 50,4 M 50,3 M
EV / Sales 2019
EV / Sales 2020 -
Nbr of Employees -
Free-Float -
Chart MINDSET PHARMA INC.
Duration : Period :
Mindset Pharma Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Income Statement Evolution
Managers and Directors
James Andre Charles Lanthier Chief Executive Officer
Arvin Ramos Chief Financial Officer
Richard J. Patricio Chairman
Joseph Araujo Director & Chief Science Officer
James Christopher Passin Director
Sector and Competitors
1st jan.Capi. (M$)
MINDSET PHARMA INC.-20.21%53
MODERNA, INC.212.57%131 807
LONZA GROUP AG32.74%61 177
IQVIA HOLDINGS INC.43.38%49 076
SEAGEN INC.-2.12%31 189
CELLTRION, INC.-39.69%25 455